LUND, Sweden, March 23, 2020 /PRNewswire/ -- BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company will submit a De Novo application ...

BONESUPPORT HOLDING AB ( (SE:BONEX)) just unveiled an announcement. BONESUPPORT has reported new U.S. clinical data demonstrating the potential of its CERAMENT G bone graft substitute in reducing ...

Results from a new study, presented at the 33rd Annual Meeting of The European Bone & Joint Infection Society, showed complete wound healing in patients with chronic osteomyelitis treated with ...

Credit: Shutterstock. Cerament G is a resorbable, gentamicin-eluting ceramic bone void filler. The Food and Drug Administration (FDA) has cleared Cerament G for use as a bone void filler in skeletally ...

The latest update is out from BONESUPPORT HOLDING AB ( (SE:BONEX)). BONESUPPORT has announced the first U.S. clinical pilot study publication on the use of its antibiotic-eluting bone graft substitute ...

Please provide your email address to receive an email when new articles are posted on . BoneSupport has announced FDA market authorization of the Cerament G bone graft for patients with osteomyelitis, ...

* NEW PRECLINICAL DATA(1) HAS BEEN PUBLISHED THAT FURTHER SUPPORT BONESUPPORT'S AMBITION TO DEVELOP A COMBINATION PRODUCT OF COMPANY'S PLATFORM TECHNOLOGY CERAMENT® AND BISPHOSPHONATE, A ...

The U.S. FDA has granted de novo approval for Bonesupport AB’s Cerament G, an antibiotic-eluting bone graft designed to osteomyelitis. The company plans to launch in the U.S. in late September or ...

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2026. "Solid start to 2026 - strong ...

BONESUPPORT HOLDING AB ((BOEUF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

Welcome, everyone, to BONESUPPORT's Q3 2025 Results Call. My name is Torbjorn Skold, and since September 1, I'm the CEO of BONESUPPORT. With me here today is our CFO, Hakan Johansson. And together, ...